Genentech licenses Arvinas' PROTAC platform

Arvinas LLC (New Haven, Conn.) granted the Genentech unit of Roche (SIX:ROG; OTCQX:RHHBY) a license to develop new therapeutics using Arvinas' protein degradation technology platform against multiple targets. Arvinas received an undisclosed upfront payment and is eligible for $300 million in milestones, plus tiered royalties. Genentech may opt to expand the deal to include more targets.

Arvinas' proteolysis-targeting chimera (PROTAC) technology uses bifunctional small molecules to label specific proteins for degradation. Arvinas declined to disclose targets for which Genentech will use the platform. Genentech did not respond to inquiries. ...